OGXI : Summary for OncoGenex Pharmaceuticals Inc. - Yahoo Finance

U.S. Markets closed

OncoGenex Pharmaceuticals, Inc. (OGXI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.58-0.02 (-2.50%)
At close: 4:00PM EST
People also watch
THLDRPRXONTXOPXACYCC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.60
Open0.60
Bid0.10 x 300
Ask0.88 x 1000
Day's Range0.58 - 0.60
52 Week Range0.33 - 1.42
Volume146,367
Avg. Volume826,875
Market Cap17.56M
Beta2.31
PE Ratio (TTM)-1.09
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals4 hours ago

    After reverse takeover, Bothell's OncoGenex changes name, focuses on smoking cessation drug

    Bothell-based OncoGenex Pharmaceuticals Inc. has signed a merger agreement with Achieve Life Science Inc. Under the terms of the proposed merger, OncoGenex (OGXI) will acquire privately traded Achieve in an all-stock transaction. The combined company will be called Achieve Life Sciences Inc., and will focus on the development of Achieve’s smoking-cessation drug, cytisine.

  • CNW Group12 days ago

    OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement

    OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement

  • PR Newswire12 days ago

    OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement

    BOTHELL, Wash. and VANCOUVER, British Columbia and MILL VALLEY, Calif., Jan. 5, 2017 /PRNewswire/ --OncoGenex Pharmaceuticals, Inc. (OGXI) ("OncoGenex"), a publicly held oncology biopharmaceutical company, and Achieve Life Science, Inc. ("Achieve"), a privately held specialty pharmaceutical company, announced today that they have entered into a definitive merger agreement under which OncoGenex will acquire Achieve in an all-stock transaction. Upon completion of the proposed merger, Achieve's equity holders are expected to own 75% of the combined company's outstanding shares and current stockholders of OncoGenex are expected to own the remaining 25% of the combined company's outstanding shares.  Following completion of the merger, OncoGenex Pharmaceuticals, Inc. will be renamed Achieve Life Sciences, Inc.